Matches in SemOpenAlex for { <https://semopenalex.org/work/W2372164443> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W2372164443 abstract "Objective To observe the effects of rosiglitazone on metabolic parameters,carotid intimamedia thickness( IMT) ,brachial-ankle pulse wave velocity( baPWV) and ankle-brachial index( ABI) in nondiabetic patients with metabolic syndrome. Methods Seventy-nine nondiabetic patients with metabolic syndrome were randomly divided into treatment group ( n = 41) and control group ( n = 38) . The patients in treatment group were treated with rosiglitazone on the basis of life-style intervention,those in control group were treated with life-style intervention for 9 months. All patients were followed up every 3 months. Body mass index ( BMI) ,waist circumference( WC) ,systolic blood pressure( SBP) ,diastolic blood pressure( DBP) ,fasting blood glucose ( FBG) ,triglyceride( TG) ,total cholesterol( TC) ,highdendity lipoprotein ( HDL-C) ,Low-density lipoprotein ( LDL) ,high sensitivity C-reactive protein ( hsCRP) ,HbA1C,fasting insulin( FIns) ,HOMA-IR,IMT,baPWV and ABI were measured in both groups before treatment and at the 6th,9th month after treatment. Results ( 1) After treatment with rosiglitazone for 6 months,FPG,TG,HDL-C,hsC RP,HbA1C,Fins and HOMA-IR in treatment group were improved ( P 0. 01) . FPG,HDL-C,hsC RP,HbA1C,Fins and HOMA-IR got further improvement at the 9th month after treatment( P 0. 01) . After 9 months,FPG,HDL-C,hsC-RP,HbA1C,Fins and HOMA-IR were changed significantly in treatment group compared to those in control group( P 0. 01) . ( 2) After treatment with rosiglitazone for 6 months,baPWV and ABI in treatment group were improved ( P 0. 01) . IMT was not changed until the 9th month after treatment. IMT,baPWV,ABI were changed significantly in treatment group compared to those in control group after 9 months ( P 0. 01) . ( 3) The reduction of HbA1C and HOMA-IR was independently related to the improvement of ABI by multivarient analysis. Conclusion In nondiabetic patients with metabolic syndrome,rosiglitazone can significantly improve insulin resistance,correct metabolic disorders,has anti-inflammatory effect and retard atherosclerosis at some extent." @default.
- W2372164443 created "2016-06-24" @default.
- W2372164443 creator A5014357245 @default.
- W2372164443 date "2010-01-01" @default.
- W2372164443 modified "2023-09-26" @default.
- W2372164443 title "Effects of Rosiglitazone on Metabolic Parameters and Large Artery Sclerosis in Nondiabetic Patients with Metabolic Sydrome" @default.
- W2372164443 hasPublicationYear "2010" @default.
- W2372164443 type Work @default.
- W2372164443 sameAs 2372164443 @default.
- W2372164443 citedByCount "0" @default.
- W2372164443 crossrefType "journal-article" @default.
- W2372164443 hasAuthorship W2372164443A5014357245 @default.
- W2372164443 hasConcept C126322002 @default.
- W2372164443 hasConcept C134018914 @default.
- W2372164443 hasConcept C164705383 @default.
- W2372164443 hasConcept C2776193436 @default.
- W2372164443 hasConcept C2778163477 @default.
- W2372164443 hasConcept C2778913445 @default.
- W2372164443 hasConcept C2779306644 @default.
- W2372164443 hasConcept C2780152017 @default.
- W2372164443 hasConcept C2780221984 @default.
- W2372164443 hasConcept C2780578515 @default.
- W2372164443 hasConcept C555293320 @default.
- W2372164443 hasConcept C71924100 @default.
- W2372164443 hasConcept C84393581 @default.
- W2372164443 hasConcept C90924648 @default.
- W2372164443 hasConceptScore W2372164443C126322002 @default.
- W2372164443 hasConceptScore W2372164443C134018914 @default.
- W2372164443 hasConceptScore W2372164443C164705383 @default.
- W2372164443 hasConceptScore W2372164443C2776193436 @default.
- W2372164443 hasConceptScore W2372164443C2778163477 @default.
- W2372164443 hasConceptScore W2372164443C2778913445 @default.
- W2372164443 hasConceptScore W2372164443C2779306644 @default.
- W2372164443 hasConceptScore W2372164443C2780152017 @default.
- W2372164443 hasConceptScore W2372164443C2780221984 @default.
- W2372164443 hasConceptScore W2372164443C2780578515 @default.
- W2372164443 hasConceptScore W2372164443C555293320 @default.
- W2372164443 hasConceptScore W2372164443C71924100 @default.
- W2372164443 hasConceptScore W2372164443C84393581 @default.
- W2372164443 hasConceptScore W2372164443C90924648 @default.
- W2372164443 hasLocation W23721644431 @default.
- W2372164443 hasOpenAccess W2372164443 @default.
- W2372164443 hasPrimaryLocation W23721644431 @default.
- W2372164443 hasRelatedWork W189432540 @default.
- W2372164443 hasRelatedWork W1993532204 @default.
- W2372164443 hasRelatedWork W2049235189 @default.
- W2372164443 hasRelatedWork W2086995303 @default.
- W2372164443 hasRelatedWork W2169668693 @default.
- W2372164443 hasRelatedWork W2356900048 @default.
- W2372164443 hasRelatedWork W2360650938 @default.
- W2372164443 hasRelatedWork W2361245615 @default.
- W2372164443 hasRelatedWork W2364232976 @default.
- W2372164443 hasRelatedWork W2368890898 @default.
- W2372164443 hasRelatedWork W2380159220 @default.
- W2372164443 hasRelatedWork W2381815844 @default.
- W2372164443 hasRelatedWork W2384567947 @default.
- W2372164443 hasRelatedWork W2388652909 @default.
- W2372164443 hasRelatedWork W2389664985 @default.
- W2372164443 hasRelatedWork W2560766289 @default.
- W2372164443 hasRelatedWork W2601040036 @default.
- W2372164443 hasRelatedWork W2902110810 @default.
- W2372164443 hasRelatedWork W3028620928 @default.
- W2372164443 hasRelatedWork W3031204520 @default.
- W2372164443 isParatext "false" @default.
- W2372164443 isRetracted "false" @default.
- W2372164443 magId "2372164443" @default.
- W2372164443 workType "article" @default.